Deals
Sanofi Agrees to Sell Five Over-the-Counter Drugs to Ipsen
- 83 million-euro purchase includes painkiller Prontalgine
- Asset sale moves Sanofi closer to complete Boehringer deal
This article is for subscribers only.
Sanofi agreed to sell some over-the-counter products to Ipsen SA as it edges closer to completing a 22.8 billion-euro ($24.2 billion) asset swap with Boehringer Ingelheim GmbH.
Ipsen will pay 83 million euros for five products including Prontalgine, a painkiller, the Paris-based company said in a statement Monday. Bloomberg previously reported the deal was close, citing a person familiar with the situation.